Encysive Pharmaceuticals — JPMorgan Healthcare Conference 2006
27 slides from Encysive Pharmaceuticals's conference presentation, Jan 9, 2006

Slide 1: JPMorgan Healthcare Conference January 9, 2006
JPMorgan Healthcare Conference January 9, 2006

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Slide 3: Introduction
Introduction Encysive is engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds in the area of vascular biology.

Slide 4: Encysive History
Encysive History TBC founded Argatroban licensed from MPC IPO IPI Acquisition 1989 1992 1993-94 1997 2000 2003 2006 GSK (SB) Argatroban ICOS-TBC JV Schering Plough Revotar Argatroban Launch Encysive Pharmaceuticals R&D Boutique Commercial Organization Thelin(tm) PDUFA

Slide 5: Investment Highlights
Investment Highlights Demonstrated ability to bring products through development Near-term FDA approval opportunity Management has successfully transformed Company into commercial organization Pipeline staged to fuel growth beyond Thelin(tm) into the next decade

Slide 6: Pulmonary Arterial Hypertension: A Growing Market Opportunity
Pulmonary Arterial Hypertension A Growing Market Opportunity

Slide 7: Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Estimated 100,000 - 200,000 patients in NA and EU Efficient, concentrated market Relatively small sales force required (est. 50-60 reps in NA) Global premium pricing opportunity Market still in its infancy Physician awareness continues to grow Tracleer(r) (bosentan) h

Slide 8: Projected PAH Diagnosis
Projected PAH Diagnosis Source: Encysive, 2005

Slide 9: Thelin: Conclusions on Clinical Benefit
Thelin(tm) __ Conclusions on Clinical Benefit Two pivotal trials completed STRIDE-2 under Special Protocol Assessment From FDA Thelin(tm) compares favorably to Tracleer(r) in STRIDE^2 31.4 meter 6MW improvement for Thelin(tm) vs 29.5 meter 6MW in for Tracleer(r) Interim, long-term data encouraging o

Slide 10: ETRAs and 6MW: Change from Baseline
24.9 22 49 58 0 37 22 38 49 0 23 29 70 Meters ETRAs and 6MW: Change from Baseline

Slide 11: ETRAs and 6MW: Change from Baseline
ETRAs and 6MW: Change from Baseline 24.9 22 49 58 0 37 22 38 49 0 23 29 70 Meters THELIN(tm) Tracleer(r) Ambrisentan STRIDE-2 STRIDE-1 Phase II Phase II Phase II ARIES II ARIES II BREATHE-1 Study 351 STRIDE-4 STRIDE-2 STRIDE-2

Slide 12: Safety and Tolerability of Thelin
Safety and Tolerability of Thelin(tm) Liver function test (LFT) elevations Class effect, seen with Tracleer(r) and ambrisentan 100 mg incidence looks reasonable (latest pivotal results: 3% for Thelin(tm), 11% for Tracleer(r)) at 18 weeks Interim data shows Thelin(tm) risk of 4% vs 14% with Tracleer(

Slide 13: Warfarin Management: STRIDE-2
Warfarin Management: STRIDE-2 0 1 2 3 Placebo Thelin(tm) 50mg Tracleer(r) Mean Warfarin Dosing Changes Per Patient per 6 week interval Warfarin Dose at wk 18 (m +- SD) 3.7 +- 2.7 2.8 +- 1.2 2.1 +- 1.0 5.1 +- 2.9 End Dose: Thelin(tm) 100mg

Slide 14: Encysive - Pipeline Positioned for Growth
Encysive- Pipeline Positioned for Growth Near-term drivers Thelin(tm) in PAH Goal of share leader Market growth Medium-term drivers New indications for Thelin(tm) I.V. formulation opportunities

Slide 15: Encysive - Pipeline Positioned for Growth
Encysive- Pipeline Positioned For Growth Long-term drivers TBC3711 in chronic indications Pre-clinical candidates Potential in-license/Acquisition

Slide 16: Pipeline Chart
Pipeline Chart PROPRIETARY PRODUCTS Thelin(tm) Oral Thelin(tm) Oral PC1 Oral PC2 Oral PC3 Intravenous PAH Undisclosed ILD Thelin(tm) Oral Undisclosed Undisclosed TBC3711 Oral Thelin(tm) Intravenous TBC3711 Intravenous Undisclosed Undisclosed Undisclosed Resistant Hyper Undisclosed PARTNERED PRODUCTS

Slide 17: Marketing in PAH
Marketing in PAH

Slide 18: Endothelial Dysfunction in PAH
Endothelial Dysfunction in PAH ET-1 is elevated (+) Vasoconstriction Cell proliferation and Hypertrophy NO and PGI2 are reduced (-) Vasodilation Anti-proliferation Anti-inflammation Anti-platelet effects ET-1 NO PGI2 Spieker LE et al. J Am Coll Cardiol. 2001;37:1493-1505. Luscher TF and Barton M. Ci

Slide 19: Combination possibilities in PAH
Combination possibilities in PAH PDE-5 Inhibitors ETRAs Prostacyclins Revatio(tm) Tracleer(r) Flolan(r) Cialis(r)* Thelin(tm)* Remodulin(r) ambrisentan* Ventavis(r) * not FDA approved for PAH * not FDA approved for PAH

Slide 20: The Key Question
The Key Question Why do we believe Thelin(tm) should win the share battle in PAH?

Slide 21: Fast followers produce more revenue (McKinsey Quarterly)
"...the first drugs to treat an ailment often fail to create more value than their later-to-market competitors do. We found that fast followers- drugs marketed 2 to 5 years after their first-in-class predecessors-typically produce significantly more revenue." - -Booth and Zemmel, The McKinsey Quarte

Slide 22: We Took a Big Pharma Approach
We Took a Big Pharma Approach Aimed at Regulatory Approvals and Marketing Success SPA with FDA Head-to-head competitor data 1,000+ patient database Broad patient inclusion criteria Well documented safety profile Highly experienced sales force hired (11 years average sales experience) Experienced pha

Slide 23: Anticipated Catalysts for 2006
Anticipated Catalysts for 2006 March PDUFA Date for Thelin(tm) Mid-Year EMEA Opinion for Thelin(tm) STRIDE-2X Data Expected at ATS in May • Long-term data: Thelin(tm) vs Tracleer(r) Results of Phase II dose-ranging trial with TBC-3711 in resistant hypertension possible by year end

Slide 24: 2005 Financial Guidance
2005 Financial Guidance $ millions Net loss FY2005 ($75.0) - ($84.0) Cash & investments at Year End $110 - $115 Actual Cash & investments at Sept. 30, 2005 $146.8

Slide 25: Thelin represents a rare opportunity
Thelin(tm) represents one of those truly rare opportunities - a product with the potential to transform an entire company. Management is focused on realizing the full potential of Thelin(tm) while positioning the pipeline for sustainable growth for the long term.

Slide 26: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Slide 27: JPMorgan Healthcare Conference January 9, 2006
JPMorgan Healthcare Conference January 9, 2006
Source: SEC EDGAR · 8-K filed Jan 9, 2006
More decks from Encysive Pharmaceuticals Inc
26th Annual JPMorgan Healthcare Conference 200825 slides · Jan 8, 2008
2007 UBS Global Life Sciences Conference21 slides · Sep 24, 2007
Cowen and Company 27th Annual Health Care Conference 200724 slides · Mar 13, 2007
BIO CEO & Investor Conference 200724 slides · Feb 13, 2007
Rodman & Renshaw Healthcare Conference 200625 slides · Nov 6, 2006
ThinkEquity Partners 4th Annual Growth Conference 200625 slides · Sep 11, 2006